Pfizer Inc.
New York, NY, US· latest recorded location
Pfizer Inc. is named on 4,443 US grants and 1,974 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 4,443
- Published applications
- 1,974
- Inventors
- 4,583
- Granted in 2026 so far
- 34
- Most recent grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 106 | 0 |
| 1977 | 94 | 0 |
| 1978 | 90 | 0 |
| 1979 | 66 | 0 |
| 1980 | 74 | 0 |
| 1981 | 92 | 0 |
| 1982 | 72 | 0 |
| 1983 | 61 | 0 |
| 1984 | 89 | 0 |
| 1985 | 72 | 0 |
| 1986 | 73 | 0 |
| 1987 | 66 | 0 |
| 1988 | 63 | 0 |
| 1989 | 79 | 0 |
| 1990 | 84 | 0 |
| 1991 | 91 | 0 |
| 1992 | 81 | 0 |
| 1993 | 68 | 0 |
| 1994 | 77 | 0 |
| 1995 | 76 | 0 |
| 1996 | 83 | 0 |
| 1997 | 102 | 0 |
| 1998 | 120 | 0 |
| 1999 | 118 | 0 |
| 2000 | 165 | 0 |
| 2001 | 177 | 50 |
| 2002 | 185 | 170 |
| 2003 | 198 | 160 |
| 2004 | 171 | 69 |
| 2005 | 164 | 62 |
| 2006 | 145 | 17 |
| 2007 | 111 | 35 |
| 2008 | 81 | 52 |
| 2009 | 83 | 36 |
| 2010 | 78 | 42 |
| 2011 | 51 | 29 |
| 2012 | 70 | 56 |
| 2013 | 37 | 44 |
| 2014 | 56 | 65 |
| 2015 | 61 | 101 |
| 2016 | 65 | 77 |
| 2017 | 66 | 99 |
| 2018 | 57 | 85 |
| 2019 | 62 | 100 |
| 2020 | 81 | 85 |
| 2021 | 57 | 96 |
| 2022 | 42 | 80 |
| 2023 | 49 | 102 |
| 2024 | 54 | 108 |
| 2025 | 46 | 82 |
| 2026 | 34 | 72 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 6,417 documents
- A61PTherapeutic uses of medicines4,305
- C07DHeterocyclic compounds3,710
- A61KMedicines and medical preparations2,580
- C07KPeptides971
- C07CAcyclic or carbocyclic compounds727
- C12NMicroorganisms or enzymes488
- C07HSugars311
- C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen249
- C07BGeneral methods of organic chemistry227
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition186
Recent patents
- Cell culture process for producing RSV F protein15 Sep 2026US 12,734,231 B2
- 5-(thiophen-2-yl)-1 H-tetrazole derivative as BCKDK inhibitors useful for treating various diseases25 Aug 2026US 12,715,863 B2
- Stable aqueous anti-TFPI antibody formulation18 Aug 2026US 12,708,668 B2
- Diacylglycerol acyl transferase 2 inhibitors11 Aug 2026US 12,703,696 B2
- Crystalline form of a SHP2 inhibitor4 Aug 2026US 12,698,271 B2
- Pyrido[4,3-d]pyrimidine compounds8 Oct 2026US 2026/0306506 A1
- Substituted pyridinone compounds and uses thereof1 Oct 2026US 2026/0294879 A1
- Compositions comprising three ospa fusion proteins for medical use1 Oct 2026US 2026/0295025 A1
- Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof24 Sep 2026US 2026/0284170 A1
- Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained24 Sep 2026US 2026/0285899 A1
Most cited
By later US patents
- Dispensing device containing a hydrophobic medium820US 5,431,921 A1995
- Alkynyl and azido-substituted 4-anilinoquinazolines379US 5,747,498 A1998
- Stereotactic surgery apparatus and method338US 4,341,220 A1982
- Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents332US 6,603,008 B12003
- Human monoclonal antibodies to CTLA-4251US 6,682,736 B12004